Pharmaceutical

Express Scripts sues FTC and demands drug pricing repor...

The company claims that the FTC’s July 2024 report is riddled with “false and mi...

FDA lifts partial clinical hold on Zentalis Pharma’s ca...

The clinical hold was placed on three studies investigating azenosertib in June ...

Equillium collaborates with Vivtex for oral formulation...

The partnership will see AI-enabled screening used to address bioavailability is...

Bicara Therapeutics closes $362m IPO in flurry of biote...

Bicara was one of three biotechs that went public last week in one of the busies...

Lilly’s EBGLYSS gains FDA approval for patients aged 12...

Eli Lilly and Company has announced the FDA approval of EBGLYSS for treating ato...

ESMO 2024: TIGIT race tightens with first look at GSK/i...

The published belrestotug/dostarlimab data is still too immature to prove the co...

ESMO 2024: Enhertu to eclipse SOC for HER2+ breast canc...

GlobalData forecasts predict Enhertu will retain its dominant market position in...

Oncternal stock crashes by 60% as it lays off staff and...

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT...

Cidara axes 30% of staff to focus on flu prevention drug

The company plans to focus its resources on conducting clinical trials for CD388...

Sobi and Enable Injections partner for Aspaveli distrib...

Sobi and Enable Injections have entered an agreement for the development and dis...

FDA approves Roche’s Tecentriq Hybreza for cancer

The US Food and Drug Administration (FDA) has approved Roche's Tecentriq Hybreza...

Into the unknown: How quickly can vaccines be developed...

R&D frameworks are in place for the next pandemic-causing pathogen, but ways to ...

Sanofi signs radioligand therapy licensing deal for rar...

Sanofi has signed a licensing agreement with RadioMedix and Orano Med to advance...

Eli Lilly to invest $1.8bn in manufacturing capacity in...

Lilly has announced a significant expansion of its manufacturing presence in Ire...

Moderna cuts five programmes to save $1.1bn in R&D costs

Moderna will slash five clinical programmes but says it remains on track for ten...

EASD 2024: Innovent shows off mazdutide’s efficacy in d...

The data from two Phase III trials demonstrated GLP-1/glucagon agonist’s efficac...